Empowered Patient Podcast

Haitham Ayad, CEO of SPIMA Therapeutics, has secured a global licensing agreement for its lead peptide-based immunotherapy candidate, which targets the Myddosome complex involved in inflammation.  This approach aims to target undruggable protein-protein interactions, leveraging the advantages of peptides over small molecules and antibodies.  In addition to inflammatory diseases like acute pancreatitis, SPIMA is also exploring the potential in certain cancers with mutations in the Myddosome complex.   Haitham explains, "In fact, what happened is that the four scientific co-founders worked together for long years to develop and to bring them to the clinical phase and to secure a global patent for that. So, at one point, the technology transfer office of the university, which is called SATT, decided that it was the appropriate moment to create a spin-off of the company so that the company could continue the work and take the lead candidate further to the clinical phase. And I joined at that point as a co-founde